CorVent Medical Launches AI/ML-Driven CorVision™ SaaS Platform and Opens Series B Financing

Audio By Carbonatix

FARGO, N.D.--(BUSINESS WIRE)--Oct 22, 2025--

CorVent Medical, Inc., an innovative medtech company applying artificial intelligence (AI) and machine learning (ML) to improve outcomes for critically ill, ventilated patients, today announced the launch of its CorVision™ intelligent ventilation software platform and the opening of its Series B financing round.

Following the commercial success of its RESPOND™ ventilator and more than $45 million raised through Series A, CorVent is now expanding its AI/ML platform strategy, supported by proceeds from the upcoming Series B, to advance critical care decision-making and drive efficiency across intensive care and emergency settings. The company plans to submit a 510(k) application to the U.S. Food and Drug Administration in November 2025, marking a significant milestone in the expansion of its digital respiratory care portfolio.

CorVent has engaged Burns McClellan, Inc. as its investor relations and strategic communications advisor to support its growth initiatives and capital market activities. In connection with the Series B, CorVent executives will attend the J.P. Morgan Healthcare Conference in January 2026 and are currently scheduling meetings with investors and strategic partners.

“Critical care teams today face an unprecedented combination of clinical complexity, staffing shortages, and rising patient acuity. With CorVision™, we are applying advanced predictive intelligence to make ventilation management safer, more efficient, and more accessible-especially in rural and resource-limited healthcare environments,” said Richard Walsh, Chief Executive Officer of CorVent Medical.

The CorVision™ SaaS platform integrates seamlessly with hospital EMR systems, telemedicine networks, and rural health infrastructures, enabling scalable solutions that strengthen healthcare system resilience and improve ventilator management at the bedside and beyond.

About CorVent Medical

CorVent Medical, Inc. is a U.S.-owned and operated medical technology company transforming respiratory care through innovation that is Simple, Safe, and Smart. Founded in 2020 to address the growing need for adaptable and affordable ventilatory support, CorVent combines clinical expertise with AI/ML driven insights to optimize healthcare outcomes for critically ill patients in both urban and rural settings.

For more information, visit www.corventmedical.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251022642361/en/

CONTACT: CorVent Medical

Media Contact: Tiffany Wirth, CMO

Email:twirth@corventmedical.comBurns McClellan for CorVent

Investor Relations

Contacts: Lee Roth / Joseph Green / Eric Ando

Email:lroth@burnsmc.com/jgreen@burnsmc.com/eando@burnsmc.com

Phone: 646-930-4406

KEYWORD: UNITED STATES NORTH AMERICA NORTH DAKOTA

INDUSTRY KEYWORD: MEDICAL SUPPLIES TECHNOLOGY FDA MANAGED CARE HEALTH HEALTH TECHNOLOGY MEDICAL DEVICES SOFTWARE ARTIFICIAL INTELLIGENCE HOSPITALS TELEMEDICINE/VIRTUAL MEDICINE

SOURCE: CorVent Medical, Inc.

Copyright Business Wire 2025.

PUB: 10/22/2025 03:43 PM/DISC: 10/22/2025 03:43 PM

http://www.businesswire.com/news/home/20251022642361/en